Literature DB >> 10753061

Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis.

S Häussler1, M Rohde, I Steinmetz.   

Abstract

Burkhloderia pseudomallei is the causative agent of melioidosis, a disease in which treatment failures and relapses are common. This study reports on slow growing B. pseudomallei 'small colony variants' (SCVs), isolated either in vitro after exposure to ceftazidime, ciprofloxacin or gentamicin or from the spleen and liver in a mouse model of melioidosis after treatment with ceftazidime. Interestingly, SCVs isolated by either method or antimicrobial agent showed a significant increase in the minimal inhibitory concentrations of various unrelated classes of antimicrobial agents. B. pseudomallei SCVs did not differ from their parental strains in standard biochemical profiles, nor by pulsed field gel electrophoresis or electron microscopy. Although the SCV phenotype was stable throughout numerous passages on antibiotic-free solid media, revertants with the parental colony morphology and, most importantly, with the parental susceptibility pattern occurred. These revertants led to rapid overgrowth of SCVs in liquid media without added antibiotics. Future studies will have to determine the clinical relevance of B. pseudomallei SCVs especially in treatment failure and relapse of infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10753061     DOI: 10.1007/s004300050110

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  18 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  Comparative physiological study of the wild type and the small colony variant of Pseudomonas aeruginosa 20265 under controlled growth conditions.

Authors:  W Sabra; A M Haddad; A-P Zeng
Journal:  World J Microbiol Biotechnol       Date:  2013-10-16       Impact factor: 3.312

3.  Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments.

Authors:  Kang Chen; Guang Wen Sun; Kim Lee Chua; Yunn-Hwen Gan
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 4.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 5.  Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.

Authors:  Herbert P Schweizer
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

6.  Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei.

Authors:  Narisara Chantratita; Drew A Rholl; Bernice Sim; Vanaporn Wuthiekanun; Direk Limmathurotsakul; Premjit Amornchai; Aunchalee Thanwisai; Hui Hoon Chua; Wen Fong Ooi; Matthew T G Holden; Nicholas P Day; Patrick Tan; Herbert P Schweizer; Sharon J Peacock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

7.  Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei.

Authors:  Mohamad A Hamad; Chad R Austin; Amanda L Stewart; Mike Higgins; Andrés Vázquez-Torres; Martin I Voskuil
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

8.  Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.

Authors:  I-Ching Sam; Kah Heng See; Savithri D Puthucheary
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

Review 9.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

10.  Selection of small-colony variants of Salmonella enterica serovar typhimurium in nonphagocytic eucaryotic cells.

Authors:  David A Cano; M Graciela Pucciarelli; Marina Martínez-Moya; Josep Casadesús; Francisco García-del Portillo
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.